Subscribe or Manage Preferences
VBCN - November 2016 Volume 3, No 3 - Multiple Sclerosis
Laura Morgan

Findings from an ongoing, phase 3 clinical trial involving patients with relapsing-remitting multiple sclerosis (MS) reveal that hematopoietic stem-cell transplantation (HSCT) may be a feasible treatment option for reversing disability associated with MS (Burt RK, et al. JAMA. 2015;313:275-284).

This randomized, open-label clinical trial investigated whether nonmyeloablative HSCT improved neurologic disability and other clinical outcomes in patients with relapsing-remitting MS, because current therapy for MS has not been able to do so.

The clinical trial is comparing the efficacy of conventional MS drugs with hematopoietic stem-cell therapy for reversing MS-related disability. Unlike standard immune-based drugs, autologous hematopoietic stem-cell therapy is designed to reset rather than suppress the immune system.

In the clinical trial, peripheral blood stem cells were collected 10 days after patients received cyclophosphamide and filgrastim. The chemotherapy conditioning regimen consisted of cyclophosphamide 5 to 2 days before stem-cell infusion plus alemtuzumab or thymoglobulin administered before stem-cell infusion.

“There has been resistance to this in the pharma and academic world,” said the trial’s coordinator, Richard K. Burt, MD, Chief, Division of Medicine-Immunotherapy and Autoimmune Diseases, Northwestern University Feinberg School of Medicine, Chicago, IL, in an interview with BBC News. “This is not a technology you can patent and we have achieved this without industry backing.”

The preliminary study results were encouraging. Dr Burt and colleagues reported that nonmyeloablative HSCT helped stop disease progression, as measured by the Expanded Disability Status Scale score, and reversed neurologic disability for many patients with relapsing-remitting MS.

Personal accounts of remarkable improvement after undergoing stem-cell transplantation for relapsing-remitting MS have recently surfaced from patients participating in this clinical trial, including Steven Storey and Holly Drewry, both of whom could walk again after being wheelchair-bound.

These preliminary findings require confirmation in randomized clinical trials, and the study is estimated to be completed by 2018.

Related Items
Can Some Patients with Multiple Sclerosis Stop Treatment?
Caroline Helwick
Web Exclusives: Value-Based Care - September 2017 published on August 30, 2017 in Multiple Sclerosis
Oral Ozanimod: A Safer Sphingosine-1-Phosphate Receptor Modulator?
Caroline Helwick
Web Exclusives: Value-Based Care - June 2017 published on June 26, 2017 in Multiple Sclerosis
Vitamin D Supplementation Shows Benefits in Multiple Sclerosis, but Questions Remain
Caroline Helwick
Web Exclusives: Value-Based Care - April 2017 published on March 31, 2017 in Multiple Sclerosis
The Causes and Consequences of Misdiagnosing Multiple Sclerosis
Chase Doyle
VBCN - November 2016 Volume 3, No 3 published on November 22, 2016 in Multiple Sclerosis
Alemtuzumab Reduces Disability in Patients with Active Relapsing-Remitting Multiple Sclerosis
Laura Morgan
VBCN - November 2016 Volume 3, No 3 published on November 22, 2016 in Multiple Sclerosis
Reducing the Cost and Improving the Care of Patients with Multiple Sclerosis
Laura Morgan
VBCN - November 2016 Volume 3, No 3 published on November 22, 2016 in Multiple Sclerosis
Experts Debate the Benefits of Early Aggressive Therapy in Multiple Sclerosis
Chase Doyle
VBCN - July 2016 Volume 3, No 2 published on July 25, 2016 in Multiple Sclerosis
Natalizumab Shows Significant Benefit in Slowing Disability Progression in Multiple Sclerosis
Chase Doyle
VBCN - July 2016 Volume 3, No 2 published on July 25, 2016 in Multiple Sclerosis
Lifestyle Enrichment May Have Some Effect on Alzheimer's Disease Biomarkers
Laura Morgan
VBCN - July 2016 Volume 3, No 2 published on July 25, 2016 in Alzheimer’s Disease/Dementia
Osimertinib Effective for First-Line Treatment of EGFR Mutation–Positive NSCLC
Laura Morgan
VBCC - June 2016, Vol 7, No 5 published on June 17, 2016 in Lung Cancer
Last modified: November 22, 2016
  • American Health & Drug Benefits
  • Lynx CME
  • Value-Based Care in Myeloma
  • Value-Based Cancer Care
  • Value-Based Care in Rheumatology